Investigational drug · Phase 2
AK146D1
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Non Small Cell Lung Cancer (NSCLC), Advanced Breast Cancer, Urothelial Carcinoma (UC).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "AK146D1"
First trial start
2026
Jun 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK146D1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Non Small Cell Lung Cancer (NSCLC)
- Advanced Breast Cancer
- Urothelial Carcinoma (UC)
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AK146D1" as an intervention, largest first.
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruiting
AkesoIndustry
NCT07669779 · 348 participants (planned) · Start Jul 10, 2026 · Primary completion Aug 30, 2027
Drug: AK146D1 for injection; AK112 Injection and 2 more · For: Advanced Non Small Cell Lung Cancer (NSCLC)
Sites: Guangzhou, China
AkesoIndustry
NCT07591090 · 200 participants (planned) · Start Jul 17, 2026 · Primary completion Sep 1, 2027
Drug: AK146D1 for injection; AK112 Injection · For: Advanced Breast Cancer
Sites: Shanghai, China
AkesoIndustry
NCT07067567 · 200 participants (planned) · Start Aug 7, 2025 · Primary completion Nov 5, 2026
Drug: AK146D1 for injection · For: Advanced Solid Tumors
Sites: Guangzhou, China
AkesoIndustry
NCT06929663 · 166 participants (planned) · Start Jul 2, 2025 · Primary completion Jun 30, 2028
Drug: AK146D1 for injection; AK112 Injection and 1 more · For: Advanced Solid Tumors
Sites: Sydney, Australia
- A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial CarcinomaNot yet recruiting
AkesoIndustry
NCT07636772 · 132 participants (planned) · Start Jun 22, 2026 · Primary completion Aug 24, 2028
Drug: AK146D1 for injection; AK112 Injection · For: Urothelial Carcinoma (UC)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.